AC IMMUNE SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.37 USD | -0.42% |
|
-2.07% | -52.60% |
| Mar. 15 | AC Immune Files $350 Million Mixed Shelf | MT |
| Mar. 14 | AC Immune SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 8.33M 9.1M | Sales 2025 * | 61.1M 66.8M | Capitalization | 204M 222M |
|---|---|---|---|---|---|
| Net income 2024 * | -66M -72.15M | Net income 2025 * | -23M -25.14M | EV / Sales 2024 * | 18.8 x |
| Net cash position 2024 * | 46.7M 51.05M | Net cash position 2025 * | 400K 437K | EV / Sales 2025 * | 3.32 x |
| P/E ratio 2024 * |
-3.29
x | P/E ratio 2025 * |
-10.2
x | Employees | 147 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 55.21% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -0.42% | ||
| 1 week | -3.27% | ||
| Current month | -19.93% | ||
| 1 month | -22.80% | ||
| 3 months | -42.20% | ||
| 6 months | -10.57% | ||
| Current year | -52.60% |
1 week
2.31
2.51
1 month
2.313.20
Current year
2.315.04
1 year
1.785.14
3 years
1.6812.61
5 years
1.6813.00
10 years
1.6819.97
| Managers | Title | Age | Since |
|---|---|---|---|
Andrea Pfeifer
FOU | Founder | 66 | 03-02-12 |
| Director of Finance/CFO | 35 | 18-12-31 | |
Nuno Mendonça
CTO | Chief Tech/Sci/R&D Officer | 42 | 23-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Douglas Williams
CHM | Chairman | 66 | 17-12-31 |
Carl June
BRD | Director/Board Member | 70 | 20-11-19 |
Werner Lanthaler
BRD | Director/Board Member | 56 | 18-07-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 2.37 | -0.42% | 322,914 |
| 24-04-23 | 2.38 | -1.65% | 189,610 |
| 24-04-22 | 2.42 | +2.54% | 208,131 |
| 24-04-19 | 2.36 | -0.84% | 316,801 |
| 24-04-18 | 2.38 | -1.65% | 369,340 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotes
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimerâs disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Calendar
2024-04-24
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.166
CHF
Average target price
9.424
CHF
Spread / Average Target
+335.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -52.60% | 224M | |
| +4.09% | 43.43B | |
| +47.81% | 41.69B | |
| +9.45% | 41.31B | |
| -10.92% | 27.14B | |
| +9.32% | 25.28B | |
| -24.87% | 18.47B | |
| +29.70% | 12.59B | |
| +1.28% | 12.33B | |
| +7.78% | 11.03B |
- Stock Market
- Equities
- ACIU Stock
